BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vadstrup K, Alulis S, Borsi A, Gustafsson N, Nielsen A, Wennerström ECM, Jørgensen TR, Qvist N, Munkholm P. Cost Burden of Crohn's Disease and Ulcerative Colitis in the 10-Year Period Before Diagnosis-A Danish Register-Based Study From 2003-2015. Inflamm Bowel Dis 2020;26:1377-82. [PMID: 31693731 DOI: 10.1093/ibd/izz265] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Sinopoulou V, Gordon M, Limketkai BN, Mullin G, Aali G, Akobeng AK; Cochrane Gut Group. Prebiotics for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2022;2022. [DOI: 10.1002/14651858.cd015084] [Reference Citation Analysis]
2 Rodríguez-Lago I, Zabana Y, Barreiro-de Acosta M. Diagnosis and natural history of preclinical and early inflammatory bowel disease. Ann Gastroenterol 2020;33:443-52. [PMID: 32879589 DOI: 10.20524/aog.2020.0508] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Kubinski R, Djamen-kepaou J, Zhanabaev T, Hernandez-garcia A, Bauer S, Hildebrand F, Korcsmaros T, Karam S, Jantchou P, Kafi K, Martin RD. Benchmark of Data Processing Methods and Machine Learning Models for Gut Microbiome-Based Diagnosis of Inflammatory Bowel Disease. Front Genet 2022;13:784397. [DOI: 10.3389/fgene.2022.784397] [Reference Citation Analysis]
4 Manceur AM, Ding Z, Muser E, Obando C, Voelker J, Pilon D, Kinkead F, Lafeuille MH, Lefebvre P. Burden of Crohn's disease in the United States: long-term healthcare and work-loss related costs. J Med Econ 2020;23:1092-101. [PMID: 32609019 DOI: 10.1080/13696998.2020.1789649] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Agrawal M, Spencer EA, Colombel JF, Ungaro RC. Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists. Gastroenterology 2021;161:47-65. [PMID: 33940007 DOI: 10.1053/j.gastro.2021.04.063] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Vadstrup K, Alulis S, Borsi A, Elkjaer Stallknecht S, Nielsen A, Rikke Jørgensen T, Wennerström C, Qvist N, Munkholm P. Societal costs attributable to Crohn’s disease and ulcerative colitis within the first 5 years after diagnosis: a Danish nationwide cost-of-illness study 2002–2016. Scandinavian Journal of Gastroenterology 2020;55:41-6. [DOI: 10.1080/00365521.2019.1707276] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
7 Ankersen DV, Weimers P, Marker D, Teglgaard Peters-Lehm C, Bennedsen M, Rosager Hansen M, Olsen J, Elmegaard Madsen M, Burisch J, Munkholm P. Costs of electronic health vs. standard care management of inflammatory bowel disease across three years of follow-up-a Danish register-based study. Scand J Gastroenterol 2021;56:520-9. [PMID: 33645378 DOI: 10.1080/00365521.2021.1892176] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Alulis S, Vadstrup K, Olsen J, Jørgensen TR, Qvist N, Munkholm P, Borsi A. The cost burden of Crohn's disease and ulcerative colitis depending on biologic treatment status - a Danish register-based study. BMC Health Serv Res 2021;21:836. [PMID: 34407821 DOI: 10.1186/s12913-021-06816-3] [Reference Citation Analysis]
9 Weimers P, Ankersen DV, Løkkegaard ECL, Burisch J, Munkholm P. Occurrence of Colorectal Cancer and the Influence of Medical Treatment in Patients With Inflammatory Bowel Disease: A Danish Nationwide Cohort Study, 1997 to 2015. Inflamm Bowel Dis 2021:izaa340. [PMID: 33409534 DOI: 10.1093/ibd/izaa340] [Reference Citation Analysis]
10 Lin YH, Lin CL, Kao CH. Adults with inflammatory bowel disease are at a greater risk of developing chronic rhinosinusitis: A nationwide population-based study. Clin Otolaryngol 2021;46:196-205. [PMID: 32886858 DOI: 10.1111/coa.13647] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Rodríguez-Lago I, Agirre U, Intxaurza N, Cantero D, Cabriada JL, Barreiro-de Acosta M. Increased use of healthcare resources during the preclinical period of inflammatory bowel disease. Dig Liver Dis 2021;53:927-30. [PMID: 33994123 DOI: 10.1016/j.dld.2021.04.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Östlund I, Werner M, Karling P. Self-monitoring with home based fecal calprotectin is associated with increased medical treatment. A randomized controlled trial on patients with inflammatory bowel disease. Scand J Gastroenterol 2021;56:38-45. [PMID: 33284639 DOI: 10.1080/00365521.2020.1854342] [Reference Citation Analysis]